Cancer

Entered into an agreement to acquire AnorMED Inc., a Canadian-based biopharmaceutical company with a late-stage Phase III hematology-oncology product, Mozobil

Market has more than doubled in the last five years—jumping from $25 billion in 2001 to $51 billion in 2005—making it the scientific trump card of the pharmaceutical industry.

Despite the elucidation of the human genome, most efforts to understand genetic changes in cancer have focused on only a handful of marker genes.

Clinicians can visualize growing tumors using positron emission tomography (PET)

Although researchers are increasingly using aptamers as high-specificity molecular probes, they generally need purified targets to generate these modified nucleic acids.

Companies are expanding a 2005 co-marketing agreement into a full-fledged collaboration to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics analysis.

Avalon and ChemDiv are combining their technologies to seek small molecules active against cancer.

Scientists scanned the phosphoprotein profile of acute myeloid leukemia (AML), identifying a novel mutant protein kinase (JAK3) that may drive AML progression

Montreal-based Genizon Biosciences occupies a rather unique position in the research of the gene-based diseases.

Lab mice may have competition in modeling human cancer, as scientists at Phylonix Pharmaceuticals successfully modeled various stages of tumor development in zebrafish.

Lentigen will collaborate with UPenn's Dr. James Riley to develop novel cancer therapies.

Elara Pharmaceuticals will be dedicated to drug development and following up on promising small molecule anti-cancer leads.